TIDMOBD
Oxford BioDynamics PLC
05 July 2022
Oxford BioDynamics Plc
Issued US reimbursement code for Checkpoint Inhibitor Response
Test (EpiSwitch(R) CiRT)
-- EpiSwitch CiRT is a f irst-of-its-kind precision medicine
test that predicts a patient's most likely response to Immune
Checkpoint Inhibitor (ICI) therapy
-- CPT PLA Code 0332U issued to Oxford BioDynamics Plc and NEXT Bio-Research Services LLC.
-- New code available for use from 1 October 2022 for insurance
reimbursement (Medicare, Medicaid or private payors)
-- A unique reimbursement code will engender physician confidence and aid the billing process
Oxford, UK - 5 July 2022 - Oxford BioDynamics Plc (AIM: OBD, the
Company), a biotechnology company developing precision medicine
tests for immune health based on the EpiSwitch 3D genomics
platform, confirms the assignment and publication of a Proprietary
Laboratory Code (PLA Code) by the American Medical Association's
CPT (Current Procedural Terminology) Editorial Board (
https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes )
.
The code, 0332U, was issued for the EpiSwitch(R) CiRT
(Checkpoint-inhibitor Response Test) to Oxford BioDynamics Plc and
its partner lab NEXT Bio-Research Service LLC. With the publication
of the code on 1 July, payors are on notice that the new code will
be available for use on and after 1 October 2022 for the billing of
the test.
"Assignment of this unique code is a critical step in the
reimbursement process," said Thomas Guiel, OBD's Chief Operating
Officer. "This code will be effective on 1 October for all requests
for insurance reimbursement, whether from Medicare, Medicaid or
private payors."
The Checkpoint inhibitor Response Test (CiRT) was launched at
the end of February 2022 as a Laboratory Developed Test (LDT). By
launching the test as an LDT, the Company was able to provide
immediate access to early adopters and generate clinical
utilization for the test. During this early phase, a miscellaneous
code has been used for reimbursement, which requires increased
communication with and explanation to payors.
The newly-published CPT PLA code is unique to OBD as
manufacturer, the Company's test and the lab. The full unique
description the editorial board assigned to the EpiSwitch(R) CiRT
(Checkpoint-inhibitor Response Test) is " Oncology (pan-tumor),
genetic profiling of 8 DNA-regulatory (epigenetic) markers by
quantitative polymerase chain reaction (qPCR), whole blood,
reported as a high or low probability of responding to immune
checkpoint-inhibitor therapy".
Jon Burrows, OBD's Chief Executive Officer said: "Gaining a
unique CPT code and descriptor for EpiSwitch(R) CiRT in the US only
four months after its launch is yet another validation of the
importance of this predictive test, the underlying EpiSwitch(R)
technology and the value it brings to the healthcare system and
oncologists. "
For more about EpiSwitch CiRT, please visit www.myCiRT.com
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
John More +44 (0)20 7408 4090
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Jonjo Cordey OxfordBioDynamics@instinctif.com
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit .
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASXLEDNAEFA
(END) Dow Jones Newswires
July 05, 2022 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024